Meningococcal vaccine groups A C Y W-135 conjugate - Novartis
Alternative Names: GSK3536820A; MCV4 vaccine; MenACWY-CRM; Menhycia; Menveo; Multivalent ACWY vaccine candidate - NovartisLatest Information Update: 01 Feb 2024
At a glance
- Originator Novartis
- Developer GSK; Novartis; Tianjin CanSino Biotechnology
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Meningococcal infections
Most Recent Events
- 26 Jan 2024 CanSino Biologics plans a phase III trial for Meningococcal infections (Prevention) (IM, Injection), in March 2024 (NCT06226714)
- 14 Nov 2023 CanSino Biologics plans a phase III trial for Meningococcal infections in Indonesia (IM, Injection) in December 2023 (NCT06131554)
- 31 Aug 2023 Tianjin CanSino Biotechnology plans a phase IIIb trial for Meningococcal infections (In children, Prevention) (IM) (NCT06011200)